Centro de Investigación en Sanidad Animal (CISA-INIA), Ctra. Algete-El Casar, 28130 Valdeolmos, Madrid, Spain.
Vaccine. 2010 Apr 9;28(17):2937-44. doi: 10.1016/j.vaccine.2010.02.018. Epub 2010 Feb 25.
In this work, plasmid constructs encoding two different M segment ORFs, as well as the nucleoprotein N, have been used in different vaccination regimes to test protection against a RVFV-MP12 virus challenge in a transgenic mouse model with impaired interferon type I response (IFNAR(-/-)). We obtained dose dependent protection in animals immunized with a construct encoding both mature glycoproteins (pCMV-M4), whereas only partial protection in animals vaccinated with either N construct (pCMV-N) or a combination of both plasmids (pCMV-M4+pCMV-N). The protection elicited by the expression of the mature glycoproteins could be directly related to the induction of neutralizing antibodies against them. Interestingly, the combination of both vaccine constructs induced specific lymphoblast proliferation upon stimulation with a recombinant nucleoprotein.
在这项工作中,我们使用了编码两种不同 M 片段 ORF 以及核蛋白 N 的质粒构建体,在具有干扰素 I 型反应缺陷(IFNAR(-/-))的转基因小鼠模型中,针对 RVFV-MP12 病毒挑战,测试了不同疫苗接种方案的保护效果。我们在使用编码两种成熟糖蛋白的构建体(pCMV-M4)免疫的动物中获得了剂量依赖性保护,而在用 N 构建体(pCMV-N)或两种质粒的组合(pCMV-M4+pCMV-N)接种的动物中仅获得部分保护。表达成熟糖蛋白所引起的保护作用可能与针对它们诱导中和抗体直接相关。有趣的是,两种疫苗构建体的组合在受到重组核蛋白刺激时诱导了特异性淋巴母细胞增殖。